肿瘤相关性高血糖管理指南(2021年版)解读

Interpretation of Guidelines for the Management of Tumor Associated Hyperglycemia(2021 Edition)

糖尿病是我国患病率最高的慢性代谢性疾病,恶性肿瘤发病率也逐年上升。研究发现,这2种疾病关系密切。临床上恶性肿瘤防治过程中相关的高血糖管理问题缺乏系统化、规范化指导。因此,在中国抗癌协会肿瘤内分泌专业委员会和重庆市中西医结合学会肿瘤内分泌分会的支持下,国内多位肿瘤学和内分泌学专家以循证医学为证据,起草了肿瘤相关性高血糖的管理指南(2021年版),对肿瘤相关性高血糖的概念、临床诊治和随访等问题进行系统详尽的介绍。本文针对该指南部分内容进行解读。

The prevalence rate of diabetes is the highest in chronic metabolic diseases of China,the incidence rate of malignant tumors is also increasing year by year,and they are closely related.Systematic and standardized guidance is deficient in the management of tumor associated hyperglycemia.Endocrinology and oncology experts from the Onco-endocrinology Society of Chinese Anti-Cancer Association and Onco-endocrinology Society of Chongqing Integrative Medicine Association have summarized the research progress and evidence-based basis of tumor associated hyperglycemia,and drafted the Guidelines for the Management of Tumor Associated Hyperglycemia(2021 Edition),which provides a systematic and detailed introduction to the conception,clinical diagnosis,treatment and follow-up of tumor associated hyperglycemia.In order to comprehend relevant opinions better,we provide an interpretation in this paper.